GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cardiovascular Systems Inc (NAS:CSII) » Definitions » Tax Expense

Cardiovascular Systems (Cardiovascular Systems) Tax Expense : $0.1 Mil (TTM As of Dec. 2022)


View and export this data going back to 2006. Start your Free Trial

What is Cardiovascular Systems Tax Expense?

Cardiovascular Systems's tax expense for the months ended in Dec. 2022 was $0.0 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2022 was $0.1 Mil.


Cardiovascular Systems Tax Expense Historical Data

The historical data trend for Cardiovascular Systems's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiovascular Systems Tax Expense Chart

Cardiovascular Systems Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.19 0.23 0.25 0.31

Cardiovascular Systems Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.05 -0.02 0.05

Cardiovascular Systems Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiovascular Systems  (NAS:CSII) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Cardiovascular Systems Tax Expense Related Terms

Thank you for viewing the detailed overview of Cardiovascular Systems's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiovascular Systems (Cardiovascular Systems) Business Description

Traded in Other Exchanges
N/A
Address
1225 Old Highway 8 Northwest, Saint Paul, MN, USA, 55112-6416
Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generate the vast majority of its revenue in the United States.
Executives
Jeffrey S. Points officer: Chief Financial Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Scott R Ward director RAYMOND HOLDINGS, LLC, 6410 BALLANTINE CT., INVER GROVE HEIGHTS MN 55077
Erik Paulsen director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Rhonda J. Robb officer: Chief Operating Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Martha Goldberg Aronson director 40 WEST HIGHLAND PARK DRIVE NE, HUTCHINSON MN 55350
Sachin H. Jain director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Alexander Rosenstein officer: General Counsel & Corp. Secy C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Sandra Sedo officer: Chief Compliance Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Kelvin K. Womack director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen J. Rempe officer: Chief Human Resources Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
John M. Hastings officer: VP Manufacturing & Operations C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen Stenbeck director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Ryan Egeland officer: VP of Medical Affairs C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
David Whitescarver officer: VP of Corp. Dev. & IP C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Laura Gillund officer: Chief Talent Officer